Novartis’ LUTATHERA (lutetium Lu 177 dotatate) has already been a breakthrough in treating gastroenteropancreatic neuroendocrine tumors (GEP-NETs). With its approval now extended to pediatric patients, Novartis further strengthens its leadership in oncology. While the lutathera cost remains a central discussion point, this expansion underscores the therapy’s value in addressing...
English
العربية
Français
Español
Português
Deutsch
Türkçe
Nederlands
Italiano
Русский
Português
Ελληνικά
Tiếng Việt